Do Wall Street Analysts Like Agilent Technologies Stock?

Core Insights - Agilent Technologies, Inc. is a leading provider of application-focused solutions in life sciences, diagnostics, and applied chemical markets, with a market capitalization of $41.6 billion [1] Stock Performance - Agilent's stock has underperformed the broader market, gaining 9.3% year-to-date and 12.8% over the past 52 weeks, compared to the S&P 500 Index's gains of 14.5% in 2025 and 13.2% over the past year [2] - The stock has outperformed the Healthcare Select Sector SPDR Fund, which gained 10.4% year-to-date and 5.1% over the past 52 weeks [3] Financial Results - Following the release of better-than-expected Q3 results, Agilent's stock rose 5.3% in a single trading session. The company reported a 10.1% year-over-year increase in net revenues to $1.7 billion, exceeding expectations by 4.6% [4] - Adjusted net income increased by 1.3% year-over-year to $390 million, with adjusted EPS of $1.37 surpassing consensus estimates by 74 basis points [4] Future Projections - For fiscal 2025, analysts expect Agilent to deliver an adjusted EPS of $5.58, reflecting a 5.5% year-over-year increase. The company has a strong earnings surprise history, surpassing bottom-line projections in the past four quarters [5] - The consensus rating among 16 analysts covering Agilent is a "Moderate Buy," consisting of nine "Strong Buys" and seven "Holds" [5] Analyst Ratings - TD Cowen analyst Dan Brennan reiterated a "Buy" rating on Agilent and raised the price target from $150 to $162, with a mean price target of $151.92 indicating a 3.5% premium to current price levels [7] - The highest street target of $170 suggests a potential upside of 15.8% [7]